Impact of sildenafil on survival of patients with eisenmenger syndrome

Journal of Clinical Pharmacology

Volumn 53, Issue 6, 2013, Pages 611-618

  Sun, Yun Juan ^a,b   Yang, Tao ^a   Zeng, Wei Jie ^c,d   Gu, Qing ^a   Ni, Xin Hai ^a   Zhao, Zhi Hui ^a   Liu, Zhi Hong ^a   Xiong, Chang Ming ^a   He, Jian Guo ^a  

^a FUWAI HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

^d THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Eisenmenger syndrome; Sildenafil; Survival

Indexed keywords

ANTICOAGULANT AGENT; DIGOXIN; DIURETIC AGENT; HEMOGLOBIN; SILDENAFIL; WARFARIN;

6 MINUTE WALK; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIURETIC THERAPY; DRUG EFFICACY; EISENMENGER COMPLEX; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HOSPITAL; HUMAN; LONG TERM CARE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TELECONSULTATION; TREATMENT DURATION; WALKING;

ADULT; ARTERIAL PRESSURE; EISENMENGER COMPLEX; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HEMOGLOBINS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PIPERAZINES; PURINES; RETROSPECTIVE STUDIES; SULFONES; SURVIVAL RATE; TIME FACTORS; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84880254046     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.78     Document Type: Article

References (28)

1. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt I. Br Med J. 1958;2:701-709.
2. Muller J, Hess J, Hager A. Exercise performance and quality of life is more impaired in Eisenmenger syndrome than in complex cyanotic congenital heart disease with pulmonary stenosis. Int J Cardiol. 2011;150:177-181.
3. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005;112:828-835.
4. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115:1039-1050.
5. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, predictors of death in Eisenmenger syndrome: a combined retrospective,case control study. Eur Heart J. 2006;27:1737-1742.
6. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration death. Eur Heart J. 1998;19:1845- 1855.
7. Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53:733-740.
8. GalieN,BeghettiM,GatzoulisMA, et al.Bosentan therapy in patients withEisenmenger syndrome: amulticenter,double blind, randomized, placebo controlled study. Circulation. 2006; 114: 48-54.
9. Mukhopadhyay S, Nathani S, Yusuf J, Shrimal D, Tyagi S. Clinical efficacy of phosphodiesterase 5 inhibitor tadalafil in Eisenmenger syndrome A randomized, placebo controlled, double blind crossover study. Congenit Heart Dis. 2011;6:424-431.
10. Rosenzweig EB, Kerstein D, Barst RJ. Long term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858-1865.
11. Beciani E, Palazzini M, Bulatovic I, et al. Effects of sildenafil treatment in patients with pulmonary hypertension associated with congenital cardiac shunts. Am J Respir Crit Care Med 2010;181: A3359.
12. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase 5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006;114:1807-1810.
13. Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open label, multicentre study. Heart. 2006;97:1876-1881.
14. Zeng WJ, Lu XL, Xiong CM, et al. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Clin Cardiol. 2011;34:513-518.
15. Lu XL, Xiong CM, Shan GL, et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther. 2010;28:350-355.
16. Brooks D, Solway S, Gibbons WJ. ATS statement on six minute walk test. Am J Respir Crit Care Med. 2003;167:1287.
17. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007;120:301-305.
18. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan sildenafil in Eisenmenger syndrome: a randomized placebo controlled double blinded trial. Eur Heart J. 2010;31:1124-1131.
19. D'Alto M, Romeo E, Argiento P, et al. Bosentan sildenafil association in patients with congenital heart disease related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2010;155:378-382.
20. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156-163.
21. Galie N, Manes A, Negro L, Palazzini M, Bacchi Reggiani ML, Branzi A. A meta analysis A randomized of controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394-403.
22. Benza RL, Miller DP, Gomberg Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122:164-172.
23. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010; 121:20-25.
24. Rubin LJ, Badesch DB, Fleming TR, et al. Long term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER 2. Chest. 2011;140:1274-1283.
25. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996;15:100-105.
26. Cantor WJ, Harrison DA, Moussadji JS, et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol. 1999;84:677-681.
27. Oya H, Nagaya N, Uematsu M, et al. Poor prognosis,related factors in adults with Eisenmenger syndrome. Am Heart J. 2002;143:739- 744.
28. Oya H, Nagaya N, Satoh T, et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart. 2000;84:53-58.